정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1241 | Active, not recruiting | Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure | Covid-19 | Biological: IMM-101 Other: Observation |
Phase 3 | Canadian Cancer Trials Group, Immodulon Therapeutics Ltd, BioCan Rx, Canadian Cancer Society (CCS), ATGen Canada Inc, Canadian Centre for Applied Research in Cancer Control (ARCC), Ontario Institute for Cancer Research | NETWORK | 195 | All | 18 Years | Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada London Regional Cancer Program, London, Ontario, Canada Ottawa Hospital Research Institute, Ottawa, Ontario, Canada Odette Cancer Centre, Toronto, Ontario, Canada University Health Network, Toronto, Ontario, Canada CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada The Research Institute of the McGill University, Montreal, Quebec, Canada CIUSSS de l'Estrie - Centre hospitalier, Sherbrooke, Quebec, Canada |
| 1240 | Not yet recruiting | Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above | COVID-19 | Biological: SARS-CoV-2 Vaccine (Vero Cell), Inactivated | Phase 3 | China National Biotec Group Company Limited, Beijing Institute of Biological Products Co Ltd. | INDUSTRY | 1800 | All | 3 Years | Sheikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates |
| 1239 | Active, not recruiting | Immunocompromised Swiss Cohorts Based Trial Platform | Immunocompromised Patients | Biological: Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) Biological: Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 μg)( Comirnaty®) |
Phase 3 | University Hospital, Basel, Switzerland, Swiss National Science Foundation | OTHER | 431 | All | 18 Years | University Hospital Basel, Basel, Switzerland University Hospital Bern, Bern, Switzerland University Hospital Lausanne CHUV, Lausanne, Switzerland University Hospital Zurich, Zurich, Switzerland |
| 1238 | Not yet recruiting | Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y) | Prevention of COVID19 | Biological: mRNA-1273 | Phase 2 | Assistance Publique - Hopitaux de Paris, Institut National de la Sante Et de la Recherche Medicale, France | OTHER | 180 | All | 18 Years | |
| 1237 | Completed | Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity | Coronavirus Disease 2019 | Biological: Recombinant new coronavirus vaccine (CHO cell) group | Not Applicable | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | INDUSTRY | 360 | All | 18 Years | Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China |
| 1236 | Not yet recruiting | Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD | COPD | Biological: Inactivated COVID-19 vaccine | Phase 4 | China National Biotec Group Company Limited, Zhejiang Provincial Center for Disease Control and Prevention, Beijing Institute of Biological Products Co Ltd. | INDUSTRY | 400 | All | 60 Years | Zhejiang provincial center for disease control and prevention, Hangzhou, Zhejiang, China |
| 1235 | Not yet recruiting | Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected | HIV Infections | Biological: Inactivated COVID-19 vaccine | Phase 4 | China National Biotec Group Company Limited, Zhejiang Provincial Center for Disease Control and Prevention, Beijing Institute of Biological Products Co Ltd. | INDUSTRY | 400 | All | 18 Years | Zhejiang provincial center for disease control and prevention, Hangzhou, Zhejiang, China |